115 related articles for article (PubMed ID: 38449377)
21. A Prospective Trial Evaluating the Safety and Systemic Response From the Concurrent Use of Radiation Therapy with Checkpoint Inhibitor Immunotherapy in Metastatic Non-Small Cell Lung Cancer.
Mattes MD; Eubank TD; Almubarak M; Wen S; Marano GD; Jacobson GM; Ma PC
Clin Lung Cancer; 2021 Jul; 22(4):268-273. PubMed ID: 33608212
[TBL] [Abstract][Full Text] [Related]
22. Treatment outcomes of stereotactic body radiation therapy for primary and metastatic sarcoma of the spine.
Kim E; Kim MS; Paik EK; Chang UK; Kong CB
Radiat Oncol; 2023 Sep; 18(1):156. PubMed ID: 37736735
[TBL] [Abstract][Full Text] [Related]
23. A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer.
Sun K; Xu Y; Zhang L; Niravath P; Darcourt J; Patel T; Teh BS; Farach AM; Guerrero C; Mathur S; Sultenfuss MA; Gupta N; Schwartz MR; Haley SL; Nair S; Li X; Nguyen TTA; Butner JD; Ensor J; Mejia JA; Mei Z; Butler EB; Chen SH; Bernicker EH; Chang JC
Clin Cancer Res; 2022 Oct; 28(20):4392-4401. PubMed ID: 35877117
[TBL] [Abstract][Full Text] [Related]
24. Effects of neoadjuvant stereotactic body radiotherapy plus adebrelimab and chemotherapy for triple-negative breast cancer: A pilot study.
Chen G; Gu X; Xue J; Zhang X; Yu X; Zhang Y; Li A; Zhao Y; He G; Tang M; Xing F; Yin J; Bian X; Han Y; Cao S; Liu C; Jiang X; Zhang K; Xia Y; Li H; Niu N; Liu C;
Elife; 2023 Dec; 12():. PubMed ID: 38131294
[TBL] [Abstract][Full Text] [Related]
25. Combining stereotactic body radiotherapy with camrelizumab for unresectable hepatocellular carcinoma: a single-arm trial.
Li JX; Su TS; Gong WF; Zhong JH; Yan LY; Zhang J; Li LQ; He ML; Zhang RJ; Du YQ; Wang XT; Liang SX; Xiang BD
Hepatol Int; 2022 Oct; 16(5):1179-1187. PubMed ID: 36001228
[TBL] [Abstract][Full Text] [Related]
26. A Pilot Study of Durvalumab (MEDI4736) with Tremelimumab in Combination with Image-Guided Stereotactic Body Radiotherapy in the Treatment of Metastatic Anaplastic Thyroid Cancer.
Lee NY; Riaz N; Wu V; Brinkman T; Tsai CJ; Zhi W; Fetten J; Ho A; Wong RJ; Ghossein R; Tuttle M; Fagin J; Pfister DG; Sherman E
Thyroid; 2022 Jul; 32(7):799-806. PubMed ID: 35521657
[No Abstract] [Full Text] [Related]
27. Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial.
Kwan EM; Spain L; Anton A; Gan CL; Garrett L; Chang D; Liow E; Bennett C; Zheng T; Yu J; Dai C; Du P; Jia S; Fettke H; Abou-Seif C; Kothari G; Shaw M; Parente P; Pezaro C; Tran B; Siva S; Azad AA
Eur Urol; 2022 Mar; 81(3):253-262. PubMed ID: 34493414
[TBL] [Abstract][Full Text] [Related]
28. Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial.
Welsh J; Menon H; Chen D; Verma V; Tang C; Altan M; Hess K; de Groot P; Nguyen QN; Varghese R; Comeaux NI; Simon G; Skoulidis F; Chang JY; Papdimitrakopoulou V; Lin SH; Heymach JV
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33051340
[TBL] [Abstract][Full Text] [Related]
29. Effect of Stereotactic Body Radiation Therapy on Diverse Organ Lesions in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors.
Zhu KK; Wei JL; Xu YH; Li J; Rao XR; Xu YZ; Xing BY; Zhang SJ; Chen LC; Dong XR; Zhang S; Li ZY; Liu CW; Meng R; Wu G
Curr Med Sci; 2023 Apr; 43(2):344-359. PubMed ID: 37002471
[TBL] [Abstract][Full Text] [Related]
30. Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma.
Curti B; Crittenden M; Seung SK; Fountain CB; Payne R; Chang S; Fleser J; Phillips K; Malkasian I; Dobrunick LB; Urba WJ
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32467299
[TBL] [Abstract][Full Text] [Related]
31. Sintilimab, stereotactic body radiotherapy and granulocyte-macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial.
Ni J; Zhou Y; Wu L; Ai X; Dong X; Chu Q; Han C; Wang X; Zhu Z
Radiat Oncol; 2021 Sep; 16(1):177. PubMed ID: 34526044
[TBL] [Abstract][Full Text] [Related]
32. A rapid and systemic complete response to stereotactic body radiation therapy and pembrolizumab in a patient with metastatic renal cell carcinoma.
Xie G; Gu D; Zhang L; Chen S; Wu D
Cancer Biol Ther; 2017 Aug; 18(8):547-551. PubMed ID: 28665741
[TBL] [Abstract][Full Text] [Related]
33. Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma.
Bahig H; Aubin F; Stagg J; Gologan O; Ballivy O; Bissada E; Nguyen-Tan FP; Soulières D; Guertin L; Filion E; Christopoulos A; Lambert L; Tehfe M; Ayad T; Charpentier D; Jamal R; Wong P
BMC Cancer; 2019 Jan; 19(1):68. PubMed ID: 30642290
[TBL] [Abstract][Full Text] [Related]
34. Stereotactic body radiotherapy extends the clinical benefit of PD-1 inhibitors in refractory recurrent/metastatic nasopharyngeal carcinoma.
Lin J; Guo Q; Guo Z; Lu T; Chen G; Lin S; Chen M; Chen C; Lu J; Zong J; Tang L; Chen Y; Pan J
Radiat Oncol; 2022 Jul; 17(1):117. PubMed ID: 35790987
[TBL] [Abstract][Full Text] [Related]
35. Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer.
Schild SE; Wang X; Bestvina CM; Williams T; Masters G; Singh AK; Stinchcombe TE; Salama JK; Wolf S; Zemla T; Duma N; Chun SG; Amini A; Kozono D; Watt C
Clin Lung Cancer; 2022 Jul; 23(5):e317-e320. PubMed ID: 35613998
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
Arrieta O; Barrón F; Ramírez-Tirado LA; Zatarain-Barrón ZL; Cardona AF; Díaz-García D; Yamamoto Ramos M; Mota-Vega B; Carmona A; Peralta Álvarez MP; Bautista Y; Aldaco F; Gerson R; Rolfo C; Rosell R
JAMA Oncol; 2020 Jun; 6(6):856-864. PubMed ID: 32271354
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of stereotactic body radiation therapy for the treatment of pulmonary metastases from sarcoma: A potential alternative to resection.
Baumann BC; Nagda SN; Kolker JD; Levin WP; Weber KL; Berman AT; Staddon A; Hartner L; Hahn SM; Glatstein E; Simone CB
J Surg Oncol; 2016 Jul; 114(1):65-9. PubMed ID: 27111504
[TBL] [Abstract][Full Text] [Related]
38. A phase 2 study of combined chemo-immunotherapy with cisplatin-pembrolizumab and radiation for unresectable vulvar squamous cell carcinoma.
Yeku O; Russo AL; Lee H; Spriggs D
J Transl Med; 2020 Sep; 18(1):350. PubMed ID: 32928237
[TBL] [Abstract][Full Text] [Related]
39. Safety and clinical efficacy of immune checkpoint inhibition and stereotactic body radiotherapy in patients with spine metastasis.
Lee E; Chen X; LeCompte MC; Kleinberg LR; Hales RK; Voong KR; Forde PM; Brahmer JR; Markowski MC; Lipson EJ; Lee SH; Bydon A; Lo SL; Lubelski D; Redmond KJ
J Neurosurg Spine; 2023 Aug; 39(2):278-286. PubMed ID: 37148233
[TBL] [Abstract][Full Text] [Related]
40. Radiation treatment planning study to investigate feasibility of delivering Immunotherapy in Combination with Ablative Radiosurgery to Ultra-High DoSes (ICARUS).
Rokni MB; Pointer KB; George J; Luke JJ; Chmura SJ; Redler G
J Appl Clin Med Phys; 2021 Mar; 22(3):196-206. PubMed ID: 33626240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
